Skip to main content

Table 2 The comparison of quantitative variables between control and treatment groups at the beginning of study

From: Safety and efficacy of platelet-rich plasma in treatment of carpal tunnel syndrome; a randomized controlled trial

Variables Group Number Mean SD P Value Power
Age Splint 20 47.23 7.11 0.06 0.419
PRP+ Splint 21 51.20 9.82
Duration Splint 20 14.13 8.55 0.09 0.064
PRP+ Splint 21 13.74 11.5
VAS Splint 20 6.24 1.17 0.28 0.443
PRP+ Splint 21 6.82 1.24
Median SNAP PL Splint 20 4.05 0.22 0.03 0.462
PRP+ Splint 21 4.25 0.52
Median CMAP OL Splint 20 4.06 0.55 0.24 0.107
PRP+ Splint 21 4.13 0.53
SSS Splint 20 2.73 0.40 0.58 0.475
PRP+ Splint 21 2.43 0.73
FS Splint 20 2.54 0.62 0.16 0.349
PRP+ Splint 21 2.36 0.83